Publications

Bejan CA, Cahill KN, Staso PJ, Choi L, Peterson JF, Phillips EJ. DrugWAS:Drug-wide association studies for COVID-19 drug repurposing. Clin Pharmacol Ther. 2021 doi: 10.1002/cpt.2376.

White AA, Cahill KN, Jerschow E, Kuruvilla M, Sehanobish E, Bensko J, Laidlaw TM, Levy JM. Covid-19 in a series of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021 doi: 10.1016/j.jaip.2021.04.060.

Toki S, Printz RL, Newcomb D, Cahill KN, Boyd KL, Niswender KD, Peebles RS. GLP-1R agonist treatment inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in a mouse model of obese asthma. Allergy. 2021 doi: 10.1111/all.14879.

Baek SH, Foer D, Cahill KN, Israel E, Maiorino E, Röhl A, Boyce JA, Weiss ST. Systems approaches to treatment response to imatinib in severe asthma: a pilot study. J Pers Med. 2021 doi:10.3390/jpm11040240.

Staso P, Wu P, Laidlaw TM, Cahill KN. Scoring tool for systemic symptoms during aspirin challenge detects mediator production aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immuno. 2021 doi: 10.1016/j.anai.2021.03.025.

Stevens WW, Jerschow E, Baptist AP, Borish L, Bosso JV, Buchheit KM, Cahill KN, Campo P, Cho SH, Keswani A, Levy JM, Nanda A, Laidlaw TM, White AA. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the rhinitis, rhinosinusitis and ocular allergy committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2020 doi: 10.1016/j.jaci.2020.10.043.

Scott W, Cahill KN, Milne G, Li P, Sheng Q, Huang LC, Dennis S, Snyder J, Bauer AM, Chandra RK, Chowdbury NI, Turner JH. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2020 doi: 10.1016/j.jaci.2020.11.001.

Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma exacerbations in type 2 diabetics with asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2020 doi:10.1164/rccm.202004-0993oc.

Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ, Breslow RG, Brockow K, Buchheit KM, Cahill KN, Cernadas J, Chiriac AM, Crestani E, Demoly P, Dewachter P, Dilley M, Farmer JR, Foer D, Fried AJ, Garon SL, Giannetti MP, Hepner DL, Hong DI, Hsu JT, Kothari PH, Kyin T, Lax T, Lee MJ, Lee-Sarwar K, Liu A, Logsdon S, Louisias M, MacGinnitie A, Maciag M, Minnicozzi S, Norton AE, Otani IM, Park M, Patil S, Phillips EJ, Picard M, Platt CD, Rachid R, Rodriguez T, Romano A, Stone CA, Torres MJ, Verdu M, Wang AL, Wickner P, Wolfson AR, Wong JT, Christina Y, Xhou J, Castells M. Practical guidance for the evaluation and management of drug hypersensitivity: Specific drugs. J Allergy Clin Immunol Pract. 8(9):S16-116, 2020.

Eid RC, Wudneh E, Zahid S, Cahill K, Jerschow E. Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 124(1):102-4, 2020.

Roland LT, Nagy C, Wang H, Moore R, Cahill KN, Laidlaw TM, Wise SK, DelGaudio JM, Kuruvilla M, Levy JM. Treatment practices for aspirin-exacerbated respiratory disease: Analysis of a national insurance claims database. Int Forum of Allergy Rhinol. 10(2):190-3, 2020.

Eid RC, Palumbo ML, Cahill KN. Perimenstrual Asthma in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract.2020 Feb;8(2):573-578.e4. doi: 10.1016/j.jaip.2019.08.054. Epub 2019 Sep 30. PubMed PMID: 31580922; PubMed Central PMCID: PMC7012664. 

Roland LT, Nagy C, Wang H, Moore R, Cahill KN, Laidlaw TM, Wise SK, DelGaudio JM, Kuruvilla M, Levy JM. Treatment practices for aspirin-exacerbated respiratory disease: analysis of a national insurance claims database. Int Forum Allergy Rhinol. 2020 Feb;10(2):190-193. doi: 10.1002/alr.22471. Epub 2019 Nov 6. PubMed PMID: 31693796; PubMed Central PMCID: PMC7060492. 

Eid RC, Wudneh E, Zahid S, Cahill K, Jerschow E. Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2020 Jan;124(1):102-104. doi: 10.1016/j.anai.2019.09.023. Epub 2019 Oct 9. PubMed PMID: 31605753; PubMed Central PMCID: PMC7114888. 

Roland LT, Wang H, Mehta CC, Cahill KN, Laidlaw TM, DelGaudio JM, Wise SK, Levy JM. Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database. Int Forum Allergy Rhinol. 2019 Dec;9(12):1420-1423. doi: 10.1002/alr.22412. Epub 2019 Aug 23. PubMed PMID: 31442000; PubMed Central PMCID: PMC6901725. 

Cahill KN, Cui J, Kothari P, Murphy K, Raby BA, Singer J, Israel E, Boyce JA, Laidlaw TM. Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. Am J Respir Crit Care Med. 2019 Sep 15;200(6):704-711. doi: 10.1164/rccm.201809-1755OC. PubMed PMID: 30978291; PubMed Central PMCID: PMC6775876. 

Huang GX, Palumbo ML, Singer JI, Cahill KN, Laidlaw TM. Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD. J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1647-1649. doi: 10.1016/j.jaip.2019.02.037. Epub 2019 Mar 12. PubMed PMID: 30877073; PubMed Central PMCID: PMC7110416. 

Mullur J, Singer J, Roditi R, Cahill KN. Hearing loss and middle ear symptoms in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1671-1672.e3. doi: 10.1016/j.jaip.2018.11.034. Epub 2018 Dec 8. PubMed PMID: 30529603; PubMed Central PMCID: PMC6511308. 

Eid RC, Palumbo ML, Laidlaw TM, Buchheit KM, Cahill KN. A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1338-1340. doi: 10.1016/j.jaip.2018.09.012. Epub 2018 Sep 25. PubMed PMID: 30261317; PubMed Central PMCID: PMC6433551. 

DeGregorio GA, Singer J, Cahill KN, Laidlaw T. A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1174-1180. doi: 10.1016/j.jaip.2018.10.032. Epub 2018 Nov 2. PubMed PMID: 30391549; PubMed Central PMCID: PMC6456426. 

Cahill KN, Murphy K, Singer J, Israel E, Boyce JA, Laidlaw TM. Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019 Feb;143(2):799-803.e2. doi: 10.1016/j.jaci.2018.10.007. Epub 2018 Oct 16. PubMed PMID: 30339852; PubMed Central PMCID: PMC6519056. 

Laidlaw TM, Cahill KN, Cardet JC, Murphy K, Cui J, Dioneda B, Kothari P, Raby BA, Israel E, Boyce JA. A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019 Jan;143(1):316-324.e7. doi: 10.1016/j.jaci.2018.06.001. Epub 2018 Jun 8. PubMed PMID: 29890239; PubMed Central PMCID: PMC6286686. 

Ordovas-Montanes J, Dwyer DF, Nyquist SK, Buchheit KM, Vukovic M, Deb C, Wadsworth MH 2nd, Hughes TK, Kazer SW, Yoshimoto E, Cahill KN, Bhattacharyya N, Katz HR, Berger B, Laidlaw TM, Boyce JA, Barrett NA, Shalek AK. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 2018 Aug;560(7720):649-654. doi: 10.1038/s41586-018-0449-8. Epub 2018 Aug 22. PubMed PMID: 30135581; PubMed Central PMCID: PMC6133715. 

Schneider TR, Johns CB, Palumbo ML, Murphy KC, Cahill KN, Laidlaw TM. Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial. J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):825-831. doi: 10.1016/j.jaip.2017.10.011. Epub 2017 Nov 10. PubMed PMID: 29133219; PubMed Central PMCID: PMC5945343. 

Tuttle KL, Buchheit KM, Laidlaw TM, Cahill KN. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1045-1047. doi: 10.1016/j.jaip.2018.01.038. Epub 2018 Mar 6. PubMed PMID: 29501519; PubMed Central PMCID: PMC5997393. 

Cahill KN. KIT Inhibition in Severe Asthma: What we learned from the KIA trial. American Academy of Allergy, Asthma and Immunology. 2018; Orlando, FL. 

Cahill KN, Boyce JA, Israel E. Novel Treatments for Airway Disease. N Engl J Med. 2017 Aug 10;377(6):597. doi: 10.1056/NEJMc1708004. PubMed PMID: 28813135. 

Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, Erzurum S, Trevor JL, Shenoy K, Chinchilli VM, Wechsler ME, Laidlaw TM, Boyce JA, Israel E. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. N Engl J Med. 2017 May 18;376(20):1911-1920. doi: 10.1056/NEJMoa1613125. PubMed PMID: 28514613; PubMed Central PMCID: PMC5568669. 

Cahill KN. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. American Thoracic Society. 2017 May; Washington, D.C.. 

Laidlaw TM, Cahill KN. Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. J Allergy Clin Immunol Pract.2017 May - Jun;5(3):537-545. doi: 10.1016/j.jaip.2016.10.021. Review. PubMed PMID: 28483309. 

Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2017 Mar;139(3):764-766. doi: 10.1016/j.jaci.2016.09.025. Epub 2016 Oct 19. PubMed PMID: 27771324. 

Cahill KN, Johns CB, Cui J, Wickner P, Bates DW, Laidlaw TM, Beeler PE. Automated identification of an aspirin-exacerbated respiratory disease cohort. J Allergy Clin Immunol. 2017 Mar;139(3):819-825.e6. doi: 10.1016/j.jaci.2016.05.048. Epub 2016 Jul 25. PubMed PMID: 27567328; PubMed Central PMCID: PMC5266739. 

Cahill KN. An Informatics Approach to Diagnosing Aspirin-exacerbated Respiratory Disease. American Academy of Allergy, Asthma and Immunology Annual Meeting. 2017; Atlanta, GA. 

Cahill KN. The Pathogenic Role of Eosinophils in Aspirin-exacerbated Respiratory Disease. American Academy of Allergy, Asthma and Immunology Annual Meeting. 2017; Atlanta, GA. 

Cahill KN, Laidlaw TM. Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2016 Nov;36(4):681-691. doi: 10.1016/j.iac.2016.06.005. Epub 2016 Sep 13. Review. PubMed PMID: 27712763. 

Shah NH, Schneider TR, DeFaria Yeh D, Cahill KN, Laidlaw TM. Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1215-1219. doi: 10.1016/j.jaip.2016.04.028. Epub 2016 Jul 7. PubMed PMID: 27396680; PubMed Central PMCID: PMC5107156. 

Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, Lai J, Bhattacharyya N, Israel E, Boyce JA, Laidlaw TM. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016 May;137(5):1566-1576.e5. doi: 10.1016/j.jaci.2015.10.020. Epub 2015 Dec 12. PubMed PMID: 26691435; PubMed Central PMCID: PMC4860132. 

Cahill KN, Katz H, Cui J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, Erzurum S, Trevor JL, Shenoy K, Chinchilli VM, Wechsler ME, Boyce JA, Israel E. Mast cell inhibition by imatinib reduces airway reactivity and improves FEV1 in severe asthma. American Thoracic Society Annual Meeting. 2016 May; San Francisco, CA, USA. 

Cahill KN, Raby BA, Zhou X, Guo F, Thibault D, Baccarelli A, Byun HM, Bhattacharyya N, Steinke JW, Boyce JA, Laidlaw TM. Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease. Am J Respir Cell Mol Biol. 2016 Jan;54(1):34-40. doi: 10.1165/rcmb.2014-0486OC. PubMed PMID: 26051534; PubMed Central PMCID: PMC4742927. 

Cahill KN. Prostaglandin D2 in the Pathogenesis of Crhonci Rhinosinusitis. American Academy of Allergy, Asthma and Immunology Annual Meeting. 2016; Los Angeles, CA. 

Stevens W, Buchheit K, Cahill KN. Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis. Curr Allergy Asthma Rep. 2015 Dec;15(12):69. doi: 10.1007/s11882-015-0569-2. Review. PubMed PMID: 26475526. 

Lee-Sarwar K, Johns C, Laidlaw TM, Cahill KN. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):449-51. doi: 10.1016/j.jaip.2015.01.007. Epub 2015 Jan 26. PubMed PMID: 25634222; PubMed Central PMCID: PMC4426242. 

Cahill KN. Identification of a Novel Endophenotype of Aspirin Exacerbated Respiratory Disease: Association with aberrant regulation of prostaglandin D2. American Academy of Allergy, Asthma and Immunology Annual Meeting. 2015 February; Houston, TX. 

Cahill KN. Aberrant Prostaglandin D2 Metabolism: Marker and pathogenetic mechanism in aspirin exacerbated respiratory disease. American Academy of Allergy, Asthma and Immunology Annual Meeting. 2015 February; Houston, TX. 

Cahill KN, Buchheit K, Word C, Borish L. Aspirin desensitization and high-dose aspirin therapy in aspirin exacerbated respiratory disease. In: Practical Medical and Surgical Management of Chronic Rhinosinusitis (. Bahtra P, Han JK, editors. New York, NY: Springer; 2015. 

Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015 Jan;135(1):245-52. doi: 10.1016/j.jaci.2014.07.031. Epub 2014 Sep 11. PubMed PMID: 25218285; PubMed Central PMCID: PMC4289104. 

Cahill KN, Laidlaw TM. Aspirin exacerbated respiratory disease: the search for a biomarker. Ann Allergy Asthma Immunol. 2014 Nov;113(5):500-1. doi: 10.1016/j.anai.2014.08.017. Epub 2014 Nov 5. PubMed PMID: 25442693. 

Cahill KN. The Role of MicroRNAs in Aspirin Exacerbated Respiratory Disease. NIAID/Asthma and Allergic Diseases Cooperative Research Centers Steering Committee Meeting. 2014 October; Rockville, MD. 

Cahill KN. Epigenetic Regulation of E Prostanoid Type 2 Receptor (EP2) in Aspirin Exacerbated Respiratory Disease. American Academy of Allergy, Asthma and Immunology Annual Meeting. 2014 March; San Diego, CA. 

Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol. 2012 Jan;8(1):43-52; quiz 53-4. doi: 10.1586/eci.11.75. Review. PubMed PMID: 22149339. 

Sheikh J, Cahill KN. Atopic and allergic features of adults with eosinophilic eosphagitis. In: Clinical Gastroenterology. Liacouras CA, Markowitz JE, editors. New York, NY: Human Press; 2012. Chapter 18; p.253-268. 

Bavbek S, Aydın O, Ataman S, Cahill K, Castells M. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy. 2011 Sep;66(9):1256-7. doi: 10.1111/j.1398-9995.2011.02601.x. Epub 2011 Apr 21. PubMed PMID: 21507006. 

Cahill K, Cheifetz A, Sheikh J. Eosinophilia in Inflammatory Bowel Disease: A case series. Allergy and asthma proceedings : the official journal of regional and state allergy societies. 2009 March; 30:206-208. 

Niederer KE, Morrow DK, Gettings JL, Irick M, Krawiecki A, Brewster JL. Cypermethrin blocks a mitochondria-dependent apoptotic signal initiated by deficient N-linked glycosylation within the endoplasmic reticulum. Cell Signal. 2005 Feb;17(2):177-86. doi: 10.1016/j.cellsig.2004.06.009. PubMed PMID: 15494209.